Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human neuregulin injection for heart failure with preserved ejection fraction
CTR20192276Phase 2Active
- Sponsor
- Zensun
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of neucardin in heart failure with preserved ejection fraction (HFpEF), sponsored by Zensun. Started Nov 2022; status: active.
02
Drugs
neucardin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on CTR20192276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192276.